Press releases
Find out more about Ferring latest announcements.
Press releases
- Uncategorized1
- TIMELINES35
- STATEMENT 20221
- STATEMENT 20213
- STATEMENT 20201
- STATEMENT 18 MARCH 20200
- PRESS RELEASE 20248
- PRESS RELEASE 202312
- PRESS RELEASE 202214
- PRESS RELEASE 20218
- PRESS RELEASE 20207
- PRESS RELEASE 20198
- PRESS RELEASE 201816
- PRESS RELEASE 201721
- PRESS RELEASE 201619
- PRESS RELEASE 201513
- PRESS RELEASE 201410
- PRESS RELEASE 20139
- PRESS RELEASE 20129
- PRESS RELEASE 20118
- PRESS RELEASE 20105
- PRESS RELEASE 200912
- PRESS RELEASE 20088
- PRESS RELEASE 20076
- PRESS RELEASE 20066
- PRESS RELEASE 20058
- PRESS RELEASE 200417
- PRESS RELEASE 200310
- PRESS RELEASE 200211
- PRESS RELEASE0
- Okategoriserad0
- NEWS 20222
- NEWS0
- GENERAL0
- FEATURES0
- BLOG2
- October 2024
- July 2024
- May 2024
- April 2024
- January 2024
- December 2023
- November 2023
- September 2023
- August 2023
- June 2023
- May 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- July 2021
- June 2021
- May 2021
- February 2021
- July 2020
- June 2020
- May 2020
- February 2020
- January 2020
- December 2019
- November 2019
- July 2019
- June 2019
- March 2019
- January 2019
- December 2018
- October 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- by siddhantFerring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle…
siddhantFerring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A novel first-in-class microbiota-based live biotherapeutic
- by siddhantFerring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A…
siddhant- siddhant